Yalonda Howze - Aug 16, 2022 Form 4 Insider Report for Codiak BioSciences, Inc. (CDAKQ)

Role
Executive Vice President, Chief Legal and Compliance Officer and Corporate Secretary
Signature
/s/ Yalonda Howze
Stock symbol
CDAKQ
Transactions as of
Aug 16, 2022
Transactions value $
-$4,297
Form type
4
Date filed
2/21/2023, 03:30 PM
Previous filing
Feb 18, 2022
Next filing
Sep 20, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CDAKQ Common Stock Options Exercise +4.86K +195.22% 7.35K Aug 16, 2022 Direct F1
transaction CDAKQ Common Stock Sale -$3.35K -1.51K -20.59% $2.21* 5.83K Aug 17, 2022 Direct F2
transaction CDAKQ Common Stock Options Exercise +4.86K +83.25% 10.7K Feb 16, 2023 Direct F1
transaction CDAKQ Common Stock Sale -$950 -1.6K -15% $0.59* 9.09K Feb 17, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CDAKQ Restricted Stock Units Options Exercise $0 -4.86K -25% $0.00 14.6K Aug 16, 2022 Common Stock 4.86K Direct F3, F4
transaction CDAKQ Restricted Stock Units Options Exercise $0 -4.86K -33.33% $0.00 9.71K Feb 16, 2023 Common Stock 4.86K Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2 The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of RSUs pursuant to a "sell to cover" provision included in the RSU Agreement.
F3 Each RSU represents a contingent right to receive one share of common stock.
F4 On February 16, 2022, the reporting person was granted 19,425 RSUs, vesting in four equal installments every six months beginning on the six month anniversary of the grant date.

Remarks:

Executive Vice President, Chief Legal and Compliance Officer and Corporate Secretary